Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

March 9, 2021

Study Completion Date

March 9, 2021

Conditions

Covid19

Interventions

DRUG

Ivermectin

Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

DRUG

Placebo

Matching Placebo to the Active IMP.

Trial Locations (1)

MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester